2019 共识声明:骨转换标志物用于亚太地区骨质疏松症治疗短期监测

2019-03-20 亚太地区骨科专家小组(统称) J Clin Densitom. 2019 Mar 20.

骨质疏松是一个主要的健康问题,到2050年,亚洲地区髋部骨折患者的数量将增加2倍以上,约占全世界髋部骨折总数的50%。本文主要针对骨转换标志物用于亚太地区骨质疏松症治疗短期监测的相关内容提供声明建议。

中文标题:

2019 共识声明:骨转换标志物用于亚太地区骨质疏松症治疗短期监测

英文标题:

Consensus Statement on the Use of Bone Turnover Markers for Short-Term Monitoring of Osteoporosis Treatment in the Asia-Pacific Region.

发布日期:

2019-03-20

简要介绍:

骨质疏松是一个主要的健康问题,到2050年,亚洲地区髋部骨折患者的数量将增加2倍以上,约占全世界髋部骨折总数的50%。本文主要针对骨转换标志物用于亚太地区骨质疏松症治疗短期监测的相关内容提供声明建议。 

拓展指南:骨质疏松相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=2019 共识声明:骨转换标志物用于亚太地区骨质疏松症治疗短期监测)] GetToolGuiderByIdResponse(projectId=1, id=16c2b1c001e378d7, title=2019 共识声明:骨转换标志物用于亚太地区骨质疏松症治疗短期监测, enTitle=Consensus Statement on the Use of Bone Turnover Markers for Short-Term Monitoring of Osteoporosis Treatment in the Asia-Pacific Region., guiderFrom=J Clin Densitom. 2019 Mar 20., authorId=null, author=, summary=骨质疏松是一个主要的健康问题,到2050年,亚洲地区髋部骨折患者的数量将增加2倍以上,约占全世界髋部骨折总数的50%。本文主要针对骨转换标志物用于亚太地区骨质疏松症治疗短期监测的相关内容提供声明建议。 , cover=, journalId=null, articlesId=null, associationId=1565, associationName=亚太地区骨科专家小组(统称), associationIntro=, copyright=0, guiderPublishedTime=Wed Mar 20 00:00:00 CST 2019, originalUrl=, linkOutUrl=, content=<div>骨质疏松是一个主要的健康问题,到2050年,亚洲地区髋部骨折患者的数量将增加2倍以上,约占全世界髋部骨折总数的50%。本文主要针对骨转换标志物用于亚太地区骨质疏松症治疗短期监测的相关内容提供声明建议。 </div> <div><br> </div>拓展指南:<strong>与<font color=red>骨质疏松</font>相关指南:</strong><br><ul><li><a href="https://www.medsci.cn/guideline/show_article.do?id=d02021c001e35792" title="原发性骨质疏松症康复干预中国专家共识" target=_blank>原发性骨质疏松症康复干预中国专家共识</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=3487e1c001e297c4" title="原发性骨质疏松症社区规范化管理方案" target=_blank>原发性骨质疏松症社区规范化管理方案</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=1718a1c001e2a56f" title="原发性骨质疏松症社区诊疗指导原则" target=_blank>原发性骨质疏松症社区诊疗指导原则</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=c08df1c001e239c3" title="2019 TES临床实践指南:女性绝经后骨质疏松症的药物治疗" target=_blank>2019 TES临床实践指南:女性绝经后骨质疏松症的药物治疗</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=d4b9f1c00169582a" title="2019 BSH最佳实践指南:接受类固醇治疗的免疫血小板减少症患者糖皮质激素性骨质疏松症的预防" target=_blank>2019 BSH最佳实践指南:接受类固醇治疗的免疫血小板减少症患者糖皮质激素性骨质疏松症的预防</a></li> 更多信息请点击:<a href="https://www.medsci.cn/guideline/list.do?q=%E9%AA%A8%E8%B4%A8%E7%96%8F%E6%9D%BE" target=_blank>有关骨质疏松更多指南</a></ul>, tagList=[TagDto(tagId=13135, tagName=骨转换标志物), TagDto(tagId=644, tagName=骨质疏松症), TagDto(tagId=89874, tagName=短期监测)], categoryList=[CategoryDto(categoryId=10, categoryName=骨科, tenant=100), CategoryDto(categoryId=21067, categoryName=梅斯医学-骨质疏松网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=0, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=4488, appHits=191, showAppHits=1, pcHits=3261, showPcHits=1658, likes=165, shares=7, comments=2, approvalStatus=1, publishedTime=Fri May 17 00:39:51 CST 2019, publishedTimeString=2019-03-20, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Fri May 17 00:39:51 CST 2019, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 17:25:47 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2019 共识声明:骨转换标志物用于亚太地区骨质疏松症治疗短期监测)])
2019 共识声明:骨转换标志物用于亚太地区骨质疏松症治疗短期监测
下载请点击:
评论区 (2)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1214752, encodeId=795f1214e5290, content=有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427d4785086, createdName=su_yi_fei, createdTime=Tue Apr 26 19:54:22 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185861, encodeId=7af2118586112, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80bb1446394, createdName=qinchjie, createdTime=Wed Jan 19 07:15:23 CST 2022, time=2022-01-19, status=1, ipAttribution=)]
    2022-04-26 su_yi_fei

    有用

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1214752, encodeId=795f1214e5290, content=有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427d4785086, createdName=su_yi_fei, createdTime=Tue Apr 26 19:54:22 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185861, encodeId=7af2118586112, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80bb1446394, createdName=qinchjie, createdTime=Wed Jan 19 07:15:23 CST 2022, time=2022-01-19, status=1, ipAttribution=)]
    2022-01-19 qinchjie

    学习

    0